Soligenix Reports Year-End 2013 Financial Results And Highlights Recent Accomplishments

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (otcqb:SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.

Help employers find you! Check out all the jobs and post your resume.